DKK3 attenuates JNK and AP-1 induced inflammation via Kremen-1 and DVL-1 in mice following intracerebral hemorrhage

Yang Xu

Loma Linda University School of Medicine

Derek Nowrangi

Loma Linda University School of Medicine

Hui Liang

Zhejiang University School of Medicine

Tian Wang

Loma Linda University School of Medicine

Lingyan Yu

Loma Linda University School of Medicine

Tai Lu

Loma Linda University School of Medicine

Zhengyang Lu

Loma Linda University School of Medicine

John H. Zhang

Loma Linda University School of Medicine

Benyan Luo

Zhejiang University School of Medicine

Jiping Tang (✉ jtang@llu.edu)

Loma Linda University <https://orcid.org/0000-0002-2392-9280>

Research

Keywords: Intracerebral hemorrhage, Inflammation, Dickkopf 3, Kremen-1, Dishevelled-1

Posted Date: December 3rd, 2019

DOI: <https://doi.org/10.21203/rs.2.17973/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background Intracerebral hemorrhage (ICH) is the most devastating stroke subtype, with a poor prognosis and few proven treatments. Neuroinflammation is associated with ICH-induced brain injury and unfavorable outcomes. There is growing evidence that dickkopf (DKK) 3 plays a key role in the adaptive anti-inflammatory and neuroprotective responses following intracerebral hemorrhage. This study aimed to evaluate the protective effects of DKK3 against brain edema and neuroinflammation in a mice model of ICH.

Methods Male, adult CD1 mice were subjected to sham or ICH surgery using a collagenase injection model. ICH animals received either recombinant DKK3, Kremen-1 siRNA, or DVL-1 siRNA. The neurobehavioral deficits were evaluated at 24 h, 72 h, and 28 days after ICH induction. Western blot and immunofluorescence were employed to examine the expression and localization of DKK3, Kremen-1, Dishevelled-1 (DVL-1), c-JUN N-terminal kinase (JNK), Activator protein-1 (AP-1), cleaved caspase-1, NF- κ B, and IL-1 β in the brain.

Results The expression of endogenous DKK3 and DVL-1 was transiently decreased after ICH compared to that in the sham group. Compared to the mice of ICH, exogenous rDKK3 administration reduced the brain water content and affected the neurological functions in ICH mice. Moreover, DKK3 was colocalized with Kremen-1 in microglia. Using a Kremen-1 or DVL-1 siRNA-induced in vivo knockdown approach, we demonstrated that the effects of DKK3 against ICH were mediated, at least partly, by the Kremen-1 and DVL-1 pathways.

Conclusions DKK3 improves the neurological outcomes, potentially by decreasing JNK/AP-1 mediated inflammation, thereby ameliorating the short- and long-term sequelae after ICH.

Background

Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes, and its mortality far exceed those of ischemic stroke. The lack of specific therapeutic targets for ICH increases the need for developing new therapeutic regimens (1). Primary brain injury occurs within a few minutes to a few hours after the onset of ICH in which the initial hematoma causes local tissue destruction from the mass effect. A secondary injury phase occurs from the breakdown of cell debris and blood components which can persist in the area surrounding the adjacent hematoma for several weeks (2). Increasing evidence has shown that neuroinflammation plays a critical role in the secondary brain injury following ICH (3-7).

Some studies have also shown that Dickkopf (DKK) 3 promotes cell survival by suppressing superoxide-producing enzyme or by inhibiting inflammation (8, 9). DKK3 is classified as a DKK glycoprotein family member that regulates cell fate during embryogenesis. DKK3 mediates potent antitumor effects, including reducing cell proliferation, anchorage-independent growth and metastasis (10-12). DKK3 antagonizes Wnt signaling by interacting with low-density lipoprotein receptor-related protein (LRP) 5/6 s (13). Therefore, DKK3 has been identified as a negative regulator of Wnt signaling in a complex and

context-dependent manner (14). Wnt principally involves the noncanonical (β -catenin-independent) and the canonical (β -catenin-dependent) signaling pathways (15). Kremen-1 is a novel transmembrane receptor that's function is Wnt inhibitory by removing LRP5/6 from the cell surface via clathrin mediated endocytosis (16, 17). Dishevelled-1 (DVL-1) is a central component to relay Wnt signaling in both canonical and non-canonical Wnt pathways, which activity and stability are strictly controlled (18). The noncanonical pathways are also involved in c-JUN N-terminal kinase (JNK) activation, which produces dominant-negative JNK and prevents pressure overload. Additionally, calmodulin-dependent protein kinase II (CAMKII) phosphorylation was associated with increased histone deacetylase phosphorylation (18). The activation of the JNK/Activator protein-1 (AP-1) signaling pathways is attributable to the increased expression of inflammatory factors in the brain (19).

DKK3, a secretory glycoprotein, is released from tissues of mice under physiological conditions in the retina, kidneys, and brain (20). Previous studies have demonstrated that DKK3 is abundant in mononuclear cells of brain, liver and heart (21). Other reports have confirmed that DKK3 is expressed in neurons and blood vessels of brain (22). In myocardial infarction conditions, the absence of DKK3 caused the increase of mortality and infarct size, along with an increased cardiomyocyte apoptosis and inflammation (9). As a smooth muscle cell differentiation factor, the absence of DKK3 also leads to atherosclerotic plaque formation by increasing vascular inflammation (23). The DKK3-mediated inflammation inhibition on myocardial infarction might be associated with the regulation of the NF- κ B pathway (9), which is also a cardioprotective regulator of pathological cardiac hypertrophy, and this function largely occurs through the inactivation of Apoptosis signal-regulating kinase (ASK1)/JNK/p38 signaling (24). Consistent with above reports, DKK3 overexpression substantially alleviated cardiac hypertrophy and fibrosis (25, 26).

Currently, the mechanisms by which DKK3 interferes with inflammation in brain tissues is still unclear. This study aims to determine the anti-inflammatory outcomes and mechanism of DKK3 in a mice model of ICH.

Material And Methods

Animals

This study was approved by the Institutional Animal Care and Use Committee at Loma Linda University. All procedures were carried out in compliance with the guidelines for Animal Experimentation of Loma Linda University. A total of 174 male CD1 mice (8-week-old, weight: 30-35 g; Charles River, Wilmington, MA, USA) were used. The animals were housed in a temperature-controlled environment with a 12 h light/dark cycle.

Experimental protocol

In the present study, all mice were randomly assigned to the following four separate experiments which are shown in the timeline of experimental design. The experimental groups and number of animals used

in experiments are listed in Figure 1.

Experiment 1

To evaluate the time course expression of endogenous DKK3 Kremen-1, DVL-1 and phosphorylated-JNK (p-JNK) in ICH mice, 36 animals were randomly divided into 6 groups for western-blot: sham and 3, 6, 12, 24, and 72 h after ICH.

Experiment 2

To assess the short and long-term neurobehavioral function, 48 mice were divided into 8 groups: sham, ICH 24 h, ICH 24 h + rDKK3 0.5 µg, ICH 24 h + rDKK3 1.5 µg, ICH 24 h + rDKK3 5 µg, sham 72 h, ICH 72 h, ICH 72 h + rDKK3 best dosage. The brain edema and neurobehavior tests were evaluated at 24 and 72 h post-ICH. The Morris water maze test was conducted on day 28 post-ICH.

Experiment 3

To determine the DKK3 intracellular localization in ICH mice, 36 animals were randomly divided into 3 groups: sham, ICH, ICH + rDKK3. The cellular localization of DKK3 was evaluated using double-labeling immunofluorescence labeling to co-localize DKK3 with ionized calcium-binding adaptor molecule 1 (Iba-1), neuronal specific nuclear protein (Neun), and Kremen-1.

Experiment 4

To explore the underlying mechanisms of DKK3-mediated anti-inflammatory effects in ICH mice, Kremen-1 siRNA and DVL-1 siRNA were administered by intracerebroventricular (ICV) injection at 24 h before ICH induction. 36 mice were randomly divided into 6 groups: sham, ICH, ICH + rDKK3, ICH + rDKK3 + scramble siRNA, ICH + rDKK3 + Kremen-1 siRNA, ICH + rDKK3 + DVL siRNA. Neurobehavioral tests and western blot analysis were performed at 24 h after ICH.

Intracerebral hemorrhage induction

ICH was induced via injection of collagenase into right basal ganglia as previously described (27). After induction of anesthesia with ketamine (100 mg/kg) and xylazine (10 mg/kg), animals were positioned prone in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). An electronic thermostat-controlled warming blanket was used to maintain the core temperature at 37 °C. ± 0.5°C. The collagenase (0.075 units in 0.5 µl saline, VII-S; Sigma, MO, USA) was injected into the right basal Ganglia. A 26-G needle was inserted with stereotaxic guidance coordinates 0.2 mm anterior, 3.5 mm ventral, and 2.2 mm lateral to the bregma at a rate of 0.1667 µl/min by a micro infusion pump (Harvard Apparatus Inc., South Natick, MA, USA). Following the infusion, the needle was left in position for an additional 10 minutes after injection to prevent the leakage of collagenase, slowly retracted, and the incision was sutured. The sham group operation received only needle insertion.

Assessment of neurological deficits

Neurological functions including modified Garcia test, wire hanging, beam balance and limb placement were evaluated in a blinded fashion (28). The independent researcher blinded to the experimental design at 24 h, 72 h and 28 d after ICH. The Garcia test includes the evaluation of spontaneous activity, axial sensation, vibrissae proprioception, symmetry of limb movement, lateral turning, forelimb walking, and climbing. In the long-term neurological study, we utilized the Morris water maze to test spatial learning capacity and memory function recovery according to previous studies (3, 27). Starting from a semi-random location, each mouse is permitted to search for a partially submerged platform for 60 seconds. Next, the mice were guided to the platform and allowed to remain for 5 seconds. The probe trial was carried out on the last day of the exam. Following learning trial, the platform was removed. The swimming path, frequency of platform crossings, latency of first platform crossing, and frequency of correct quadrant crossings were recorded with a camera and linked to a computer tracking system (Noldus Ethovision, WA, USA).

Evaluation of brain water content

Mice were euthanized at 24 h or 72 h post-ICH. The brains were immediately removed and dissected into 5 parts: ipsilateral and contralateral basal ganglia and cortex. The cerebellum was employed as the internal control. Each part was weighed on an electronic analytical balance (APX-60, Denver Instrument, NY, USA) giving the wet weight (WW) and then dried at 100 °C for 24 h to determine the dry weight (DW). The brain water content was calculated as $[(WW - DW) / WW] \times 100\%$.

Drug and siRNA Administration

Three different formats of Kremen-1 siRNA or DVL-1 siRNA (OriGene Technologies, MD, USA) were diluted with transfection reagent (Entranser™, Engreen Biosystem). ICV administration was performed at 24 h before ICH as previously described (29-31). The Kremen-1 siRNA, DVL-1 siRNA, and scramble siRNA mixture (100 pmol in 2 µL) was delivered into the ipsilateral ventricle, administration at a rate of 0.667 µl/min. rDKK3 (SRP6268, Sigma-Aldrich, MO, USA) was dissolved in 10 µl of saline and three different doses (0.5 µg, 1.5 µg, and 5.0 µg per mouse) were designed. rDKK3 was administered via intranasal route at 1 hr post-ICH.

Western blot analysis

Mice hemispheres were isolated and stored at -80 °C until protein extraction. The ipsilateral brain hemispheres were homogenized in RIPA lysis buffer (sc-24948, Santa Cruz, TX, USA) and then centrifuged (14,000 g at 4 °C for 30 min). Equal amounts of protein (50 µg) were loaded and subjected to electrophoresis on an SDS-PAGE gel. After being transferred to a nitrocellulose membrane, they are blocked with 5% nonfat milk (Bio-Rad Laboratories, Irvine, CA, USA). The membrane was incubated with the primary antibody overnight at 4 °C. The primary antibodies were used as follows: anti-DKK3 (1:1000, ab186409, Abcam, MA, USA), anti-Kremen-1 (1:500, ab86636, Abcam, MA, USA), anti-DVL-1 (1:1000, ab174679, Abcam, MA, USA), anti-AP-1 (1:200, NBP1-89544, Novusbio, CO, USA), anti-caspase-1 (1:1000, NBP1-45433, Novusbio, CO, USA), anti-IL-1β (1:500, sc-7884, Santa Cruz, TX, USA) and anti-p-c-Jun N-

terminal kinase (p-JNK) (1:500, ab131499, Abcam, MA, USA). The blot bands were quantified using ImageJ (NIH). The results were expressed as ratio of the target band intensity to the band intensity of β -actin (1:1000, sc-58673, Santa Cruz, TX, USA) and then normalized to the mean sham group ratio.

Immunofluorescence staining

Mice were perfused under deep anesthesia with isoflurane, followed by infusion of 4% paraformaldehyde. The brains were then removed and fixed in formalin at 4 °C overnight followed by dehydration with 30% sucrose in PBS. The frozen coronal slices (10 mm thick) were sectioned in cryostat (CM3050S; Leica Microsystems, Bannockburn). Brain slice were hydrated and blocked with 5% normal goat serum. Sections were incubated overnight at 4°C with the following primary antibodies: anti-DKK3 (1:100, ab186409, Abcam, MA, USA), anti-Kremen-1 (1:100, ab86636, Abcam, MA, USA). Then they were incubated by appropriate fluorescence-conjugated secondary antibodies (1:100, AB2337972, AB2338059, AB2340432 or AB233887, Jackson ImmunoResearch Laboratories, PA, USA) at room temperature for 2 h. Sections were observed using an OLYMPUS BX51 microscope.

Statistical Analysis

All values are presented in the text as mean $\pm$ Standard Deviation (SD). Western blot data were analyzed using one-way ANOVA with Tukey post hoc tests. Behavior data were analyzed using one-way ANOVA on ranks with Tukey post hoc tests or repeated measures ANOVA when appropriate. All histological data were analyzed using one-way ANOVA with Student-Newman's post hoc tests. Statistical significance implies $p < 0.05$.

Results

Endogenous levels of DKK3, Kremen-1, DVL-1 and p-JNK in ICH mice

Western blotting showed that the expression of DKK3 transiently decreased after ICH (* $p < 0.05$ versus sham; Figure 2B) compared to that of the sham group at 6 h to 72 h after ICH. Kremen-1 showed no change at any time point (Figure 2C). DVL-1 decreased at 12 h after ICH ($p < 0.05$ versus sham; Figure 2D). An elevation of p-JNK was observed at 3 h and reached a peak at 12 h after ICH. The level of p-JNK began to decline at 24 h but remained statistically significant to sham through 72 h ($p < 0.05$ versus sham; Figure 2E).

rDKK3 improved the neurological functions and reduced the brain water content at 24 and 72 h after ICH

Three different doses of rDKK3 (0.5 μ g, 1.5 μ g, and 5.0 μ g) were administered intranasally at 1 hr after ICH induction. The mice in the vehicle group showed statistically decreased performance in the Garcia test, limb placement test, and corner turn test at both 24 h and 72 h after ICH compared to those of the sham group (Fig. 3 A-F). rDKK3 (5.0 μ g) improved the neurological functions in all the same tests at 24 and 72 h after ICH compared to those in the vehicle group ($p < 0.05$ versus vehicle).

The brain water content in the vehicle group showed significant elevation in ipsilateral basal ganglia at both 24 and 72 h (* $p < 0.05$ versus sham; Figure 3G, H). Compared to the vehicle group, rDKK3 treatment reduced the ICH-induced brain water content in the ipsilateral basal ganglia at 24 and 72 h after ICH (# $p < 0.05$ versus vehicle). The 24 hr results indicated that the high dose of rDKK3 (5.0 μg) showed the greatest improvements and was thus selected as the dosage for the 72 hr experiment and other experiments.

rDKK3 improved long-term neurobehavior

To examine the long-term neurological impairment and neurological function, Morris water maze tests were performed at four weeks post-ICH. The results showed that the escape latency and swimming distance of the vehicle group were significantly longer compared to sham (* $p < 0.05$ versus sham; Figure 4A, B). The rDKK3 group exhibited an improved performance in escape latency and swimming distance on the 5th day of training compared to vehicle. Though not statistically significant to vehicle ($p > 0.05$), rDKK3 did show improvement by not being statistically significant to sham in the probe quadrant duration (Figure 4C). However, comparing the velocity did not show significant changes between any of the groups ($p > 0.05$; Figure 4D).

rDKK3 treatment reduces the expression of inflammatory markers after ICH

Vehicle groups show decreased expression of DKK3 after ICH at 24 h consistent with our previous results (* $p < 0.05$ versus sham; Figure 5A and B). After rDKK3 administration, the total level of DKK3 increased when compared with the vehicle group (# $p < 0.05$ versus vehicle; Figure 5A and B). Inflammatory factors, including TNF- α and IL-1 β expression, increased after ICH in the vehicle group compared to sham (* $p < 0.05$; Figure 5A, C, and D). rDKK3 administration reversed these changes and showed significantly decreased expression of TNF- α and IL-1 β as compared to vehicle (# $p < 0.05$; Figure 5A, C, and D). The immunofluorescence results showed that the fluorescence intensity of DKK3 outside of the cell membrane in vehicle and DKK3 treatment groups was slightly reduced when compared to sham (Figure 5E).

Co-localization of DKK3 and Kremen-1 in microglia and neurons after ICH

Dual-immunofluorescence staining was performed in the perihematomal brain tissue 24 h following hemorrhage induction. The staining showed that both DKK3 and Kremen-1 were colocalized with microglia (CD68) and neurons (Neun; Figure 6B and C). Interestingly, most of Kremen-1 was visualized as a ring. Immunofluorescence co-labeling of DKK3 with Kremen-1 was detected in the vehicle group (Figure 6D).

Knockdown of Kremen-1 or DVL-1 reversed the effects of the rDKK3-mediated inhibition of inflammation after ICH

The ICH mice were given rDKK3 in addition to either Kremen-1 siRNA, DVL-1 siRNA, or scramble siRNA. Western blot analysis was done at 24 h after ICH (Figure 7A). Results showed that the expression of DKK3 and DVL-1 was significantly decreased at 24 h after ICH (* $p < 0.05$ versus sham group; Fig. 7B, and

D). Additionally, p-JNK, AP-1, cleaved caspase-1, and IL-1 β were significantly elevated in the vehicle group compared to the sham group (* $p < 0.05$; Figure 7E-H). rDKK3 administration showed increased DKK3 and DVL-1 expression (# $p < 0.05$; Figure 7B and D) and decreased p-JNK, AP-1, cleaved caspase-1, and IL-1 β compared to vehicle (# $p < 0.05$; Figure 7E-H). Kremin-1 siRNA and DVL-1 siRNA showed successful knockdown of expression of Kremin-1 and DVL-1 respectively (* $p < 0.05$; Figure 7C and D). Kremin-1 siRNA and DVL-1 siRNA given with rDKK3 showed reversal of expression changes seen from rDKK3 treatments alone. Both Kremin-1 siRNA and DVL-1 siRNA groups showed increasing expression of inflammatory factors p-JNK, AP-1, cleaved caspase-1, and IL-1 β compared to sham (* $p < 0.05$) and the scramble siRNA group (@ $p < 0.05$; Figure 7E-H). Additionally, Kremin-1 siRNA showed significant elevation of AP-1 versus vehicle (# $p < 0.05$; Figure 7F) and DVL-1 siRNA showed increase in IL1 β compared to vehicle (# $p < 0.05$; Figure 7H).

The rDKK3-mediated improvement in neurobehavior functions was reversed with Kremin-1 siRNA or DVL-1 siRNA

The results showed that the neurobehavior function significantly improved at 24 h after rDKK3 administration, as evaluated by the modified Garcia test, limb placement test, and corner turn test consistent with our previously results (# $p < 0.05$ versus vehicle; Figure 8A-C). Kremin-1 siRNA and DVL-1 siRNA given with rDKK3 showed reversal of these improvements and showed a significant decrease in neurobehavior scores compared to sham (* $p < 0.05$; Figure 8A-C).

Discussion

In this study, we demonstrate that the administration of rDKK3 showed beneficial outcomes following the conditions of ICH. The inflammatory response in ICH is related to the recruitment of inflammatory cells and to the activation of a series of inflammatory cascades. A reduction in inflammatory infiltrates is associated with an attenuation of brain injury of ICH (32-34). Previously, DKK3 was observed at high levels in the liver, heart, kidney and brain (35-38). DKK3 overexpression substantially alleviated cardiac hypertrophy and fibrosis (10). We showed that rDKK3 inhibits ICH-induced inflammation, leading to improved neuroprotection after experimental ICH in mice.

Intranasal administration allows many drugs to avoid BBB and reach the cerebrospinal fluid via olfactory sensory neurons (39). Thus, in the present study, rDKK3 was intranasally administered. Three doses of rDKK3 (0.5 μ g, 1.5 μ g, and 5.0 μ g) were evaluated in the ICH mouse model. Our results showed that treatment with rDKK3 at dose of 5.0 μ g not only improved neurological function but also significantly reduced cerebral edema at 24 and 72 h after ICH. (Fig. 3). Additionally, we found that long-term neurological deficits were also improved based on the water maze assessment (Fig. 4). This suggests that DKK3 provides a neuroprotective therapy in a setting of ICH.

Although it has been shown that DKK3 protects neurons against a variety of toxic insults via mediating vascular endothelial growth factor (VEGF), the complete biological action of DKK3 is still not fully understood (20). Previous studies have also shown that DKK3 may reduce activation of inflammatory

pathways such as JNK1/2 and p38 pathways as observed in myocardial infarction (9). In this study, we found that a decreased DKK3 expression was accompanied by an increase of inflammatory factors after ICH. By treating ICH mice with rDKK3, we observed significant decreases in the release of inflammatory factors, such as TNF- α , cleaved caspase-1, and IL-1 β (Fig. 5). This suggests to us that DKK3 modulates inflammation. The specific receptors and related signaling pathways that DKK3 interacts with are still controversial compared to those of the other DKK family members. It has been proposed that the DKK3-Kremen-1 interaction may affect Wnt signaling through unknown mechanisms (40). Nicola confirmed that Kremen-1, but not Lipoprotein receptor-related protein 6 (LRP6), immunoprecipitated with DKK3 in cancer-associated fibroblasts, and the mRNA levels of Kremen-1 were not altered after DKK3 silencing (41). In the present study, Kremen-1 did not show any change in expression during the same timeframe when DKK3 levels were observed to be reduced after ICH. We observed that utilizing Kremen-1 siRNA together with rDKK3 reduced the protective ability shown with rDKK3 alone (Fig. 2). This suggests the connection of DKK3 to the Kremen-1 receptor.

We also found that DKK3 and Kremen-1 were expressed in neurons and microglia after ICH (Fig. 6). Of interest was our observation of the Kremen-1 pattern changes in neurons. Kremen-1 formed a ring at the edge of the cell membrane suggesting it is cell surface membrane bound when there was a reduction in DKK3 as seen during the ICH setting. This is consistent with previous studies such as in a tumor microenvironment where DKK3 and Kremen-1 colocalized to internal structures; however, after DKK3 silencing, Kremen-1 localized to the cell periphery (41). DKK3 distribution was also found to be disrupted following ICH injury showing decreased expression (Fig. 5E). These findings suggest that endogenous DKK3 shapes the responsiveness of neurons to inflammatory insults.

We also found that the ICH injury caused a gradual decline in the endogenous expression of DVL-1 from 12 h to 72 h after ICH. The reduction in the cascade of DKK3 and DVL-1 after ICH may be a protective mechanism of DKK3. Yu and colleagues also demonstrated that DVL-1 and JNK are potential signaling pathways that relay DKK3 signaling in endothelial cells (42). However, to our knowledge, we are the first to demonstrate its signaling pathways being potentially associated in microglia. The loss of DKK3 led to the inflammatory cell infiltration accompanied by an increased p-JNK expression in the brain, supporting the deterioration of behavioral data (Fig.5).

Based on our results, we can conclude that DVL-1 play a major role in the downstream signaling involved in the DKK3 mechanism. These results show that rDKK3 administration increases DVL-1 and decreases JNK, AP-1, cleaved caspase-1, and IL-1 β (Fig. 7). These protein expression changes of rDKK3 were reversed by the knockdown of Kremen-1 and DVL-1 using siRNAs showing that these proteins mediate the signal of DKK3. The neurobehavioral findings indicated that the neuroprotective effect of DKK3 after ICH is mediated by DVL-1 and Kremen-1 (Fig. 8).

Our data strongly suggest that the suppression the downstream protein JNK/AP-1 largely account for the neuroprotective action of DKK3. However, one of the major limitations of this study is that we paid special attention to the involvement of DKK3 to the Kremen-1 receptor and that other potential

mechanisms have been neglected. DKK3 has been previously reported to inhibit inflammation through the noncanonical Wnt signaling pathway in a model of atherosclerosis. This mechanism promoted reendothelialization and induced endothelial cell migration (42). Furthermore, DKK3 has also been observed in a cardioprotective model to interrupt the ASK1–JNK/p38 signaling cascades (9). In addition, though we primarily explored the protective effects of DKK3 on the inflammatory process, we also observed that neurons may be affected by the pathway as well potentially contributing to the improved behavioral outcomes we observed. Therefore, DKK3 might represent a promising therapeutic target for ICH and neuron injury as well.

In conclusion, this study proposed that DKK3 inhibits the inflammatory reactions induced by ICH. The underlying mechanism of the protective role of DKK3 in ICH via Kremen-1 and DVL-1 to inhibit JNK/AP-1 signaling pathway (Fig. 9). The complete mechanism of DKK3 signaling is complex and is dynamically regulated during brain development through its crosstalk with many signaling pathways. Further research is needed to elucidate the precise mechanism by which DKK3 regulates DVL-1 signaling. Our results indicate a neuroprotective role in reducing inflammation in an experimental model of ICH. Therefore, we propose that DKK3 administration may provide a promising therapy to the pathology of ICH and brain injury.

Abbreviations

AP-1: Activator protein-1; Cont-BG: Contralateral basal ganglia; Cont-CX: Contralateral cortex; CAMKII: Calmodulin-dependent protein kinase II; DKK: Dickkopf; ICH: Intracerebral hemorrhage; IL-1 β : Interleukin-1 beta; Ipsi-BG: Ipsilateral basal ganglia; Ipsi-CX: Ipsilateral cortex; JNK: c-JUN N-terminal kinase; LRP: Lipoprotein receptor-related protein; VEGF: Vascular endothelial growth factor.

Declarations

Ethics approval

This study was approved by the Institutional Animal Care and Use Committee at Loma Linda University. All procedures were carried out in compliance with the care and the Use of Laboratory Animals (National Research Council) and complied with the ARRIVE guidelines for reporting in vivo experiments.

Consent for publication

Not applicable.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

No competing interests.

Funding

This study was supported partially by grants NS091042 and NS082184 from the National Institutes of Health, and grants from National Natural Science Foundation of China (81701161 and 81671143).

Authors' contributions

JHZ, YX, and JPT conceived and designed the study. YX, HL, LYY, TL, and ZYL performed the experiments and collected the data. DN, TW, and BYL contributed to analyzing the data and drafting this article. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Author details

1. Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institutes, Wannan Medical College, Anhui 241000, China
2. Department of Basic Sciences, Division of Physiology, Loma Linda University School of Medicine, CA 92350, USA
3. Department of Anesthesiology, Loma Linda University School of Medicine, CA 92350, USA
4. Department of Neurology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang 310003, China
5. Department of Neurology, Wannan Medical College First Affiliated Hospital, Anhui 241000, China

References

1. Joseph MJ, Caliaperumal J, Schlichter LC. After Intracerebral Hemorrhage, Oligodendrocyte Precursors Proliferate and Differentiate Inside White-Matter Tracts in the Rat Striatum. *Translational stroke research*. 2016;7(3):192-208.
2. Lu Z, Wang Z, Yu L, Ding Y, Xu Y, Xu N, et al. GCN2 reduces inflammation by p-eIF2 α /ATF4 pathway after intracerebral hemorrhage in mice. *Experimental neurology*. 2019;313:16-25.
3. Lu T, Wang Z, Prativa S, Xu Y, Wang T, Zhang Y, et al. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/beta-catenin pathway activation in a mouse model. *Journal of neurochemistry*. 2019;148(1):114-26.
4. Krafft PR, McBride D, Rolland WB, Lekic T, Flores JJ, Zhang JH. α 7 Nicotinic Acetylcholine Receptor Stimulation Attenuates Neuroinflammation through JAK2-STAT3 Activation in

Murine Models of Intracerebral Hemorrhage. *BioMed research international*. 2017;2017:8134653. 5. Ma L, Manaenko A, Ou YB, Shao AW, Yang SX, Zhang JH. Bosutinib Attenuates Inflammation via Inhibiting Salt-Inducible Kinases in Experimental Model of Intracerebral Hemorrhage on Mice. *Stroke*. 2017;48(11):3108-16. 6. Chen S, Yang Q, Chen G, Zhang JH. An update on inflammation in the acute phase of intracerebral hemorrhage. *Translational stroke research*. 2015;6(1):4-8. 7. Zhang P, Wang T, Zhang D, Zhang Z, Yuan S, Zhang J, et al. Exploration of MST1-Mediated Secondary Brain Injury Induced by Intracerebral Hemorrhage in Rats via Hippo Signaling Pathway. *Translational stroke research*. 2019. 8. Qui S, Kano J, Noguchi M. Dickkopf 3 attenuates xanthine dehydrogenase expression to prevent oxidative stress-induced apoptosis. *Genes to cells : devoted to molecular & cellular mechanisms*. 2017;22(4):406-17. 9. Bao MW, Cai Z, Zhang XJ, Li L, Liu X, Wan N, et al. Dickkopf-3 protects against cardiac dysfunction and ventricular remodelling following myocardial infarction. *Basic research in cardiology*. 2015;110(3):25. 10. Gu YM, Ma YH, Zhao WG, Chen J. Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro. *World journal of gastroenterology*. 2011;17(33):3810-7. 11. Mizobuchi Y, Matsuzaki K, Kuwayama K, Kitazato K, Mure H, Kageji T, et al. REIC/Dkk-3 induces cell death in human malignant glioma. *Neuro-oncology*. 2008;10(3):244-53. 12. Than SS, Kataoka K, Sakaguchi M, Murata H, Abarzua F, Taketa C, et al. Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma. *Oncology reports*. 2011;25(4):989-95. 13. Fujii Y, Hoshino T, Kumon H. Molecular simulation analysis of the structure complex of C2 domains of DKK family members and beta-propeller domains of LRP5/6: explaining why DKK3 does not bind to LRP5/6. *Acta medica Okayama*. 2014;68(2):63-78. 14. Veeck J, Dahl E. Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. *Biochimica et biophysica acta*. 2012;1825(1):18-28. 15. McEnerney L, Duncan K, Bang BR, Elmasry S, Li M, Miki T, et al. Dual modulation of human hepatic zonation via canonical and non-canonical Wnt pathways. *Experimental & molecular medicine*. 2017;49(12):e413. 16. Sumia I, Pierani A, Causeret F. Kremen1-induced cell death is regulated by homo- and heterodimerization. *Cell death discovery*. 2019;5:91. 17. Mulvaney JF, Thompkins C, Noda T, Nishimura K, Sun WW, Lin SY, et al. Kremen1 regulates mechanosensory hair cell development in the mammalian cochlea and the zebrafish lateral line. *Scientific reports*. 2016;6:31668. 18. Lu D, Bao D, Dong W, Liu N, Zhang X, Gao S, et al. Dkk3 prevents familial dilated cardiomyopathy development through Wnt pathway. *Laboratory investigation; a journal of technical methods and pathology*. 2016;96(2):239-48. 19. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. *Neurobiology of disease*. 2009;34(1):95-106. 20. Busceti CL, Di Menna L, Bianchi F, Mastroiacovo F, Di Pietro P, Traficante A, et al. Dickkopf-3 Causes Neuroprotection by Inducing Vascular Endothelial Growth Factor. *Frontiers in cellular neuroscience*. 2018;12:292. 21. Zhang K, Watanabe M, Kashiwakura Y, Li SA, Edamura K, Huang P, et al. Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development. *International journal of oncology*. 2010;37(6):1495-501. 22. Bruggink KA, Kuiperij HB, Gloerich J, Otte-Holler I, Rozemuller AJ, Claassen JA, et al. Dickkopf-related protein 3 is a potential Abeta-associated protein in Alzheimer's Disease. *Journal of neurochemistry*. 2015;134(6):1152-62. 23. Karamariti E, Zhai C, Yu B, Qiao L, Wang Z, Potter CMF, et al. DKK3 (Dickkopf 3) Alters Atherosclerotic Plaque Phenotype Involving Vascular Progenitor and Fibroblast Differentiation Into

Smooth Muscle Cells. Arteriosclerosis, thrombosis, and vascular biology. 2018;38(2):425-37. 24. Zhang Y, Liu Y, Zhu XH, Zhang XD, Jiang DS, Bian ZY, et al. Dickkopf-3 attenuates pressure overload-induced cardiac remodelling. Cardiovascular research. 2014;102(1):35-45. 25. Akazawa H, Komuro I. Dickkopf-3: a stubborn protector of cardiac hypertrophy. Cardiovascular research. 2014;102(1):6-8. 26. Zhai CG, Xu YY, Tie YY, Zhang Y, Chen WQ, Ji XP, et al. DKK3 overexpression attenuates cardiac hypertrophy and fibrosis in an angiotensin-perfused animal model by regulating the ADAM17/ACE2 and GSK-3beta/beta-catenin pathways. Journal of molecular and cellular cardiology. 2017;114:243-52. 27. Rolland WB, Lekic T, Krafft PR, Hasegawa Y, Altay O, Hartman R, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Experimental neurology. 2013;241:45-55. 28. Krafft PR, Altay O, Rolland WB, Duris K, Lekic T, Tang J, et al. alpha7 nicotinic acetylcholine receptor agonism confers neuroprotection through GSK-3beta inhibition in a mouse model of intracerebral hemorrhage. Stroke. 2012;43(3):844-50. 29. Iniahe LO, Krafft PR, Klebe DW, Omogbai EKI, Zhang JH, Tang J. Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage. Neurobiology of disease. 2015;82:349-58. 30. Chen S, Zhao L, Sherchan P, Ding Y, Yu J, Nowrangi D, et al. Activation of melanocortin receptor 4 with RO27-3225 attenuates neuroinflammation through AMPK/JNK/p38 MAPK pathway after intracerebral hemorrhage in mice. Journal of neuroinflammation. 2018;15(1):106. 31. Chen S, Zuo Y, Huang L, Sherchan P, Zhang J, Yu Z, et al. RO27-3225 attenuates NLRP1-dependent neuronal pyroptosis via MC4R/ASK1/JNK/p38 MAPK pathway in a mouse model of intracerebral hemorrhage. British journal of pharmacology. 2019. 32. Wang Z, Zhou F, Dou Y, Tian X, Liu C, Li H, et al. Melatonin Alleviates Intracerebral Hemorrhage-Induced Secondary Brain Injury in Rats via Suppressing Apoptosis, Inflammation, Oxidative Stress, DNA Damage, and Mitochondria Injury. Translational stroke research. 2018;9(1):74-91. 33. Wu B, Ma Q, Khatibi N, Chen W, Sozen T, Cheng O, et al. Ac-YVAD-CMK Decreases Blood-Brain Barrier Degradation by Inhibiting Caspase-1 Activation of Interleukin-1beta in Intracerebral Hemorrhage Mouse Model. Translational stroke research. 2010;1(1):57-64. 34. Wang T, Nowrangi D, Yu L, Lu T, Tang J, Han B, et al. Activation of dopamine D1 receptor decreased NLRP3-mediated inflammation in intracerebral hemorrhage mice. Journal of neuroinflammation. 2018;15(1):2. 35. Xie L, Wang PX, Zhang P, Zhang XJ, Zhao GN, Wang A, et al. DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity. Journal of hepatology. 2016;65(1):113-24. 36. Cao Q, Zhang J, Gao L, Zhang Y, Dai M, Bao M. Dickkopf3 upregulation mediates the cardioprotective effects of curcumin on chronic heart failure. Molecular medicine reports. 2018;17(5):7249-57. 37. Zhu X, Li W, Li H. miR-214 ameliorates acute kidney injury via targeting DKK3 and activating of Wnt/beta-catenin signaling pathway. Biological research. 2018;51(1):31. 38. Fukusumi Y, Meier F, Gotz S, Matheus F, Irmeler M, Beckervordersandforth R, et al. Dickkopf 3 Promotes the Differentiation of a Rostrolateral Midbrain Dopaminergic Neuronal Subset In Vivo and from Pluripotent Stem Cells In Vitro in the Mouse. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2015;35(39):13385-401. 39. Patel GB, Zhou H, Ponce A, Chen W. Safety evaluation of calcium administered intranasally to mice. International journal of toxicology. 2009;28(6):510-8. 40. Nakamura RE, Hackam AS. Analysis of Dickkopf3 interactions with Wnt signaling receptors. Growth factors. 2010;28(4):232-42. 41. Ferrari N, Ranftl R, Chicherova I, Slaven ND, Moeendarbary E, Farrugia AJ, et al. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive

behaviours in cancer-associated fibroblasts. Nature communications. 2019;10(1):130. 42. Yu B, Kiechl S, Qi D, Wang X, Song Y, Weger S, et al. A Cytokine-Like Protein Dickkopf-Related Protein 3 Is Atheroprotective. Circulation. 2017;136(11):1022-36.

Figures

Figure 1

Study Design Representative figure showing experimental design and number of animals for each group. ICH, Intracerebral hemorrhage; WB, Western Blot; rDKK3, recombinant DKK3.

Figure 2

Expression of DKK3, Kremen-1, DVL-1 and p-JNK in the ipsilateral hemispheres after intracerebral hemorrhage. Representative Western blotting images of DKK3, Kremen-1, DVL-1 and p-JNK (A). Bar graphs of the quantitative analysis of DKK3 (B), Kremen-1 (C), DVL-1 (D) and p-JNK (E) expression in the ipsilateral hemisphere after ICH. Data are expressed as the mean $\pm$ SD, * p < 0.05 versus sham, n = 6 animals per group.

Figure 3

Effects of rDKK3 on the neurological outcome, brain water content, escape latency and swimming distance after ICH. Garcia test score (A), left forelimb placement (B), and corner turn test (C) at 24 h after ICH. Garcia test score (D), left forelimb placement (E), and corner turn test (F) at 72 h after ICH. Brain water content 24 h (G) and 72 h (H) after ICH. Data are expressed as the mean $\pm$ SD, * p < 0.05 versus sham; # p < 0.05 versus vehicle, n = 6 animals per group.

Figure 4

Administration of rDKK3 improved neurological function at 28 d after ICH. Morris water maze test spatial learning performance was analyzed with the escape latency (A) and swimming distance (B). The duration in the probe quadrant (C) and velocity (D) 28 d after ICH. * $p < 0.05$ versus sham; # $p < 0.05$ versus vehicle, $n = 6$ animals per group.

Figure 5

Expression of DKK3, TNF- α , and IL-1 β . Representative Western blotting images of DKK3, TNF- α and IL-1 β in the ipsilateral brain tissue (A). Bar graphs of the quantitative analysis of DKK3 (B), TNF- α (C) and IL-1 β (D) expression after ICH or rDKK3 treatment. Data are expressed as the mean $\pm$ SD, *p < 0.05 versus sham; #p < 0.05 versus vehicle, n = 6 animals per group. Representative images of DKK3-positive cells in the perihematoma brain tissue (E). Scale bar: 50 μ m, n = 6 animals per group.

Figure 6

Endogenous expression of DKK3 and Kremen-1 after ICH in microglia and neurons. Brain samples were obtained from the perihematomal area of the brain tissue (shown with a gray shadow) 24 h following ICH (A). Representative images of immunofluorescence staining showing the expression of (B) DKK3 (red) and (C) Kremen-1 (red), colocalizing with the activated microglia marker CD68 (green) and neuronal marker Neun (green). DKK3 (green) colabeled with Kremen-1 (red) (D). Scale bar: 20 μ m, n = 6 animals per group.

Figure 7

Western blot of rDKK3/Kremen-1/DVL-1 mechanistic pathway. Representative Western blot bands (A) and the densitometric quantification of DKK3 (B), Kremen-1 (C), DVL-1 (D), p-JNK (E), AP-1 (F), cleaved caspase-1 (G) and IL-1 β (H) in the sham, vehicle, rDKK3, rDKK3 + scrambled siRNA, rDKK3 + Kremen-1 siRNA, and rDKK3 + DVL-1 siRNA groups 24 h after ICH. Data are expressed as the mean $\pm$ SD. *p < 0.05 versus sham; #p < 0.05 versus vehicle; @ < 0.05 vs rDKK3 + scramble siRNA group, n = 6 animals per group.

Figure 8

Neurological function at 24 hrs showing effects of Kremen-1 and DVL-1 siRNA Modified Garcia test (A), limb placement test (B), and corner turn test (C) in the sham, vehicle, rDKK3, rDKK3 + Scrambled siRNA, rDKK3 + Kremen-1 siRNA, rDKK3 + DVL-1 siRNA groups 24 h after ICH. Data are expressed as the mean $\pm$ SD. * $p < 0.05$ versus sham; # $p < 0.05$ versus vehicle; @ < 0.05 vs rDKK3 + scramble siRNA group, $n = 6$ animals per group.

Figure 9

Mechanism Representation in a microglia ICH induces JNK/AP-1 activation thus leading to an increase in Caspase-1 and producing an inflammatory response. Administration of rDKK3 activates Kremen-1 (phosphorylated) and triggers DVL-1 activation, thus reducing JNK/AP-1 signaling and reducing inflammation. Administration of Kremen-1 and DVL-1 siRNA should reduce the effects of DKK3/Kremen-1/DVL-1 thus reducing the beneficial effects of rDKK3 on ICH induced inflammation.